SCHEMBL113563

SCHEMBL113563

CCCOCn1cnc2cc(OC)c(OC)cc21

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FGFR1 P11362 2/20 0.44
SRC P12931 2/20 0.44
MEN1 O00255 1/20 0.42
KMT2A Q03164 1/20 0.42
HDAC6 Q9UBN7 3/20 0.40
LMNA P02545 2/20 0.40
ENPP1 P22413 1/20 0.39
KDR P35968 1/20 0.39
TNF P01375 3/20 0.38
GAA P10253 2/20 0.37
MAPT P10636 2/20 0.37
TP53 P04637 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
IKBKE Q14164 1/20 0.36
QPCT Q16769 2/20 0.36
QPCTL Q9NXS2 2/20 0.36
KDM4E B2RXH2 1/20 0.36
HPGD P15428 1/20 0.36
HSD17B10 Q99714 1/20 0.36
HDAC3 O15379 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2141789 0.86 SRC (0.43) FGFR1SRCMEN1KMT2AHDAC6
SCHEMBL2268683 0.81 LMNA (0.51) FGFR1SRCMEN1KMT2AHDAC6
SCHEMBL2273596 0.81 FGFR1 (0.51) FGFR1SRCMEN1KMT2AHDAC6
SCHEMBL1193136 0.78 MEN1 (0.45) FGFR1SRCMEN1KMT2ALMNA
SCHEMBL24344854 0.76 MEN1 (0.37) FGFR1SRCMEN1KMT2AHDAC6
SCHEMBL29513592 0.76 MEN1 (0.37) FGFR1SRCMEN1KMT2AHDAC6
SCHEMBL30986474 0.76 MEN1 (0.37) FGFR1SRCMEN1KMT2AHDAC6
SCHEMBL25944454 0.75 NPC1 (0.47) FGFR1MEN1KMT2ALMNAGAA
SCHEMBL9598443 0.74 MEN1 (0.49) FGFR1SRCMEN1KMT2AHDAC6
SCHEMBL9569986 0.74 MEN1 (0.49) FGFR1SRCMEN1KMT2AHDAC6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2424843-B1 IMIDAZOLE DERIVATIVES AND THEIR USE AS MODULATORS OF CYCLIN DEPENDENT KINASES NOVARTIS AG (CH) 2014-03-26 EP disclosed
US-8598217-B2 Imidazole derivatives and their use as modulators of cyclin dependent kinases ASTEX THERAPEUTICS LTD. (GB) 2013-12-03 US disclosed
US-20120101064-A1 IMIDAZOLE DERIVATIVES AND THEIR USE AS MODULATORS OF CYCLIN DEPENDENT KINASES ASTEX THERAPEUTICS LIMITED (GB) 2012-04-26 US disclosed
EP-2424843-A1 IMIDAZOLE DERIVATIVES AND THEIR USE AS MODULATORS OF CYCLIN DEPENDENT KINASES Novartis AG (CH) 2012-03-07 EP disclosed
WO-2010125402-A1 IMIDAZOLE DERIVATIVES AND THEIR USE AS MODULATORS OF CYCLIN DEPENDENT KINASES NOVARTIS AG (CH) 2010-11-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120101064-A1 IMIDAZOLE DERIVATIVES AND THEIR USE AS MODULATORS OF CYCLIN DEPENDENT KINASES CDK3, CCNI, CDK1 FGFR1 701/4885SRC 352/4885MEN1 2006/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.